Judge: Amgen will not have to put drug prices in TV ads
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara Biotherapeutics reports $58 million net loss
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
SerImmune gets $8 million in financing from Illumina Ventures
Santa Barbara immunotherapy and diagnostic company SerImmune received $8 million in financing from San Francisco-based Illumina Ventures to expand its immune mapping platform and database. Illumina invests primarily in early-stage companies researching genomics, life science and health care. A subsidiary of pharmaceutical giant Merck also participated in the financing round, alongside other undisclosed investors. Mapping Read More →
Agilent cancer treatment approved in Europe
Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
